GP KFPs / SAQs · dermatological-presentations
Atopic eczema — KFP-style written assessment
KFP-style staged scenarios on atopic eczema: diagnosis and steroid phobia, emollient quantities and fingertip units, site-matched potency, calcineurin inhibitors, infected eczema and the eczema herpeticum emergency, bleach baths, dupilumab escalation and sleep burden.
On this page
Study tools
Target exams
RACGP KFPRACGP AKTMRCGP AKT
Prompt
Atopic eczema: diagnose clinically, moisturise generously, match potency to site, treat infection fast
KFP 1 (10 marks)
An 8-month-old has weeping facial and extensor-surface eczema failing soap-based bathing. The mother uses a fingertip of hydrocortisone 1% across the whole body once weekly because she read that steroids "thin the skin". Sleep is broken every night. [5][6]
- Name the two management errors and the correct approach for each. (4) [5]
- Address the mother's steroid fear with safety numbers. (3) [8][6]
- Prescribe the emollient regimen with quantities. (3) [5]
Model answers
- Error one: soap-based bathing — switch to soap substitute/emollient wash. Error two: under-dosing (one fingertip for the whole body is far below requirement; face needs ~2.5 FTUs alone per application) applied too infrequently. Correct approach: generous emollient twice daily plus mild-potency steroid (hydrocortisone 1–2.5%) to the face daily until clear, then step down; review within one-to-two weeks. [5]
- Cochrane NMA found no increased skin thinning with short-term use of any potency; over long courses thinning occurred in only 0.3%. Adrenal suppression on biochemical testing was 3.8% in children across observational studies and reversed when treatment ceased. Untreated eczema itself causes scarring, sleep loss and suffering — under-treatment is the real harm. [8][6]
- Emollient ointment or cream, roughly 250 g per week scaled for her size, applied at least twice daily and after every wash in downward strokes; use an emollient soap-substitute for bathing. Expect to re-prescribe monthly — running out early signals correct use. [5]
References8ShowHide
- [1]Long CC et al. The finger-tip unit--a new practical measure. Clinical and experimental dermatology, 1991.PMID 1806320
- [2]Simpson EL et al. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. The New England journal of medicine, 2016.PMID 27690741
- [3]Blauvelt A et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS). The Lancet, 2017.PMID 28478972
- [4]George SM et al. Interventions to reduce Staphylococcus aureus in the management of eczema. The Cochrane database of systematic reviews, 2019.PMID 31684694
- [5]Stacey SK et al. Topical Corticosteroids: Choice and Application. American family physician, 2021.PMID 33719380
- [6]Axon E et al. Safety of topical corticosteroids in atopic eczema: an umbrella review. The British journal of dermatology, 2021.PMID 34233978
- [7]Bakaa L et al. Bleach baths for atopic dermatitis: A systematic review and meta-analysis including unpublished data, Bayesian interpretation, and GRADE. Journal of the American Academy of Dermatology, 2022.PMID 35367346
- [8]Lax SJ et al. Topical Anti-Inflammatory Treatments for Eczema: A Cochrane Systematic Review and Network Meta-Analysis. JAMA dermatology, 2024.PMID 39219446